# Revolution Medicines (RVMD) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/RVMD
## Company Profile
- Ticker: RVMD
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 205.26 USD
- Market cap: 32167970665.22 USD
- Last updated: 2026-08-12
## Business Overview
### RAS(ON) Inhibitors
Revolution Medicines develops oral targeted therapies that bind active, GTP-loaded RAS proteins. Its portfolio covers multiple RAS mutations and combination strategies across pancreatic and lung cancers.
### Daraxonrasib
Daraxonrasib is a multi-selective RAS(ON) inhibitor and the company's lead late-stage asset. It has demonstrated Phase 3 survival benefit in previously treated metastatic pancreatic cancer.
### Pancreatic-Cancer Franchise
Beyond second-line disease, RASolute 304 evaluates daraxonrasib in resectable pancreatic cancer after surgery, while another registrational program addresses first-line metastatic disease.
### Zoldonrasib
Zoldonrasib selectively targets RAS G12D and is being developed in lung cancer as monotherapy, with standard of care and in an inhibitor-doublet combination with daraxonrasib.
### Elironrasib
Elironrasib is a covalent RAS G12C-selective inhibitor. Revolution Medicines is defining its registrational strategy within a broader mutation-specific portfolio.
### Lung-Cancer Development
RASolve 301 evaluates daraxonrasib in previously treated non-small cell lung cancer, while RASolve 308 is a planned first-line Phase 3 study of zoldonrasib plus standard therapy.
## Why The Stock Is Moving

As of Aug 12, 2026, RVMD was little changed and closed at $205.26. No new same-company headline was identified in the current news window.

## Future Catalysts

- Detailed Phase 3 RASolute 302 results at an ASCO 2026 plenary session.
- Global regulatory submissions, including a U.S. NDA, for daraxonrasib in previously treated pancreatic cancer.
- Initiation of the Phase 3 RASolve 308 study in the first half of 2026.
- Substantial completion of enrollment in RASolve 301 during 2026.
- Initiation of a registrational zoldonrasib-plus-daraxonrasib study in the second half of 2026.

## Recent News
- 2026-08-10 10:01 EST — [Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration](https://biopharmsignal.com/news/RVMD/revolution-medicines-and-beone-medicines-announce-clinical-development-and-regio-a4f15a3d) — Source: Revolution Medicines
- 2026-08-05 20:02 EST — [Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress](https://biopharmsignal.com/news/RVMD/revolution-medicines-reports-second-quarter-2026-financial-results-and-update-on-fd8742ee) — Source: Revolution Medicines
- 2026-07-29 20:05 EST — [Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026](https://biopharmsignal.com/news/RVMD/revolution-medicines-to-report-financial-results-for-second-quarter-2026-after-m-4ad84d96) — Source: Revolution Medicines
- 2026-07-22 20:05 EST — [Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-new-drug-application-for-daraxonrasib-accepted-for-review-b-f594345f) — Source: Revolution Medicines
- 2026-07-07 13:24 EST — [European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process](https://biopharmsignal.com/news/RVMD/european-medicines-agency-expedites-assessment-of-revolution-medicines-daraxonra-a47b14e8) — Source: Revolution Medicines